Jonathan Corren, Stanley J Szefler, Ellen Sher, Phillip Korenblat, Weily Soong, Nicola A Hanania, Gary Berman, Guy Brusselle, Ralph Zitnik, Chitra R Natalie, Luna Sun, Kimberly Siu, Wen-Shuo Wu, Peter Lio, April W Armstrong
BACKGROUND: LAVOLTA (L)I, LII, and ACOUSTICS were randomized, placebo-controlled, Phase 3 trials of lebrikizumab, a monoclonal antibody targeting interleukin-13, in patients with uncontrolled asthma. Failure to demonstrate efficacy may have been related to patient selection in those trials. OBJECTIVE: To assess the efficacy in a well-defined subpopulation of patients with elevated blood eosinophil counts and a minimum number of prior asthma exacerbations. An additional analysis in a subpopulation of patients with elevated fractional exhaled nitric oxide (FeNO) and prior exacerbations was performed...
February 13, 2024: Journal of Allergy and Clinical Immunology in Practice